Invus
VC Fund
New York, United States
Invus is a VC fund in New York focused on Biotechnology and Health Care. Invus recognizes that every company is unique and that extraordinary business performance cannot be achieved by following a formulaic approach. Due to their unique structure, they have a great deal of flexibility in the types of companies and situations where they can get involved.They know that real transformation takes time and that it is nevera straight line. They fully align their incentives with their partners and have the wherewithal and long-term commitment to see through any bumps along the way.They have been successfully empowering owner-managers since 1985. They have been reinvesting the same pool of money from the same group of European families (through their Artal investment vehicle) since their founding. Today they manage over $4 billion in an evergreen fund and work out of offices in New York, London, Paris and Hong Kong.
- Total investments:
- 284
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Invus invests in
Stages Invus invests in
Countries Invus invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $14M–$200M
- Series B
- $35M–$230M
- Series C
- $31M–$165M
Investment Focus
Industry
- Biotechnology 115 (40%)
- Health Care 67 (24%)
- Therapeutics 52 (18%)
- Medical 37 (13%)
- Life Science 32 (11%)
Stage
- Series B 56 (20%)
- Series C 38 (13%)
- Series A 35 (12%)
- Post-IPO Equity 27 (10%)
- Funding Round 17 (6%)
Country
- United States 123 (43%)
- France 11 (4%)
- China 4 (1%)
- United Kingdom 4 (1%)
- Switzerland 3 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Benedetto Staccia
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
|
Christopher Marsh
Private Equity Senior Associate
|
Private Equity Senior Associate | Total investments: 0 | Find email | |
Evren Bilimer
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
Addy Ho
Vice President
|
Vice President | Total investments: 0 | Find email | |
Benjamin Tsai
Partner
|
Partner | Total investments: 6 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Agenus
|
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers,vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing.It was established in 1994 and is headquartered in Lexington, Massachusetts. | $85M / Post-IPO Debt / Jul 13, 2026 | |
Flare Therapeutics
|
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | |
Lycia Therapeutics
|
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M / Series D / Jun 25, 2026 | |
Absci
|
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $100M / Post-IPO Equity / Jun 24, 2026 | |
City Therapeutics
|
City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M / Series B / Jun 08, 2026 | |
Contraline
|
Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible. | $92.5M / Series B / Jun 02, 2026 | |
Whitehawk Therapeutics
|
Aadi Bioscience was founded by Dr. Neil Desai, is a clinical-stage biopharmaceutical company developing the potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases. | $87.5M / Post-IPO Equity / May 13, 2026 | |
Ray Therapeutics
|
Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases. | $125M / Series B / Apr 21, 2026 | |
Egetis Therapeutics
|
Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development. | $38.3M / Post-IPO Equity / Apr 21, 2026 | |
Doctolib
|
Doctolib is an online booking platform and management software provider for doctors in Europe working with 65 000 health practitioners, present in 1 300 health facilities. 25 million patients visit Doctolib website and mobile app every month.For doctors, Doctolib is a full-range service to improve bookings management, reduce no-show and bring newpatients to your office. For patients, Doctolib is a free online service to find a nearby health practitioner and book doctor or dentist appointments 24/24 and 7/7 within a few clicks.Founded in 2013, Doctolib is based out of Paris, France. | $346.2M / Secondary Market / Apr 02, 2026 | |
| See all 284 investments → | |||
Co-Investors
RA Capital Management
36 deals together
Google Ventures
29 deals together
Janus Henderson Investors
25 deals together
Samsara BioCapital
25 deals together
T. Rowe Price
25 deals together
ARCH Venture Partners
24 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Invus invest in?
Invus invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 284 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Invus's check size?
Invus typically joins rounds of $14M–$200M at Series A, $35M–$230M at Series B and $31M–$165M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Invus participates in.
How do I contact Invus?
Public channels for Invus include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Invus?
The team at Invus includes Benedetto Staccia (Managing Director), Christopher Marsh (Private Equity Senior Associate) and Evren Bilimer (Managing Director), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
